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Immune therapy for cancer is being pursued with extraordinary
interest by investigators and pharma industries, given the new
scientific acquisitions on immune mechanisms that control cancer
and the introduction to clinical use of checkpoint inhibitor
molecules, ipilimumab (anti-CTLA4) and nivolumab/pembrolizu-
mab (PD-1/PDL-1 inhibitors) among others.1
The paradigm for immune therapy of cancer is allogeneic stem
cell transplantation, whose therapeutic effect is carried out by
immunocompetent T cells of the donor, an effect known as graft-
versus-leukemia or graft-versus-tumor effect (GVT).2 After anec-
dotal reports in breast and lung cancer, Childs et al.3 reported in
2000 a consistent GVT effect of allogeneic stem cell transplant
against renal cell cancer. GVT effect was then investigated in other
tumors: As STWP of the EBMT, we completed several studies of
allografting in selected solid tumors, namely renal cell cancer,4
ovarian cancer,5 breast cancer,6 colorectal cancer7 and others, with
circumstantial evidence of GVT in some tumors and occurrence of
transplant-related toxicities, mostly GvHD. In renal cell cancer, we
have shown a long-term survival effect in a fraction (20%) of
patients.8
Since 2004, when molecularly targeted drugs were introduced
into the clinic for renal cell cancer (for example, sorafenib and
sunitinib), patient referral for transplant dropped precipitously,
and transplant rate evaluation for solid tumors from 2009 was
limited to a few patients in Europe (Figure 1).
We were interested to know whether allografting for solid
tumors should be considered to be an obsolete procedure, or if it
still has a place in the therapeutic armamentarium of transplant
clinicians. In February 2015, before the Annual Meeting of the
EBMT in Istanbul, we scrutinized the EBMT Registry, and retrieved
all cases of allotransplant in solid tumors performed in adult
patients (418-year old) in the years 2009–2014. Six hundred and
forty Centers routinely report their transplant activity to the EBMT
Registry: overall, 38 centers from 8 countries performed an
allogeneic stem cell transplant procedure in 63 patients
with solid tumors. The Centers were located in 8 European
countries (Table 1). In the 2009–2014 time period, the median
number of allogeneic transplant in solid tumors was 1 per Center
(range 1–6).
We sent a questionnaire to the EBMT centers that had
performed allogeneic transplants in solid tumors in that time
period. Questions investigated the interest to pursue allografting
in solid tumors in the context of EBMT protocols, in detail:
1. Did you perform transplant on a compassionate basis?
2. Do you have a protocol for such transplants?
J if yes: would you be willing to share your protocol with other
interested EBMT centers?
J if not: would you be interested in an EBMT protocol for this
disease?
3. Would you be interested to provide information on your
transplants for a publication?
4. Based on your previous experience, would you continue to
offer patients with solid tumors an allogeneic SCT?
Thirty eight Centers who had transplanted 63 patients were
contacted. Eighteen (47%) agreed to contribute data, for a total of
32 patients (51%). The diagnoses of the allografted patients are
reported in Table 2. Twelve centers had performed transplants on
a compassionate basis (that is, without a clinical protocol; 67%), six
had at least one protocol in place for solid tumors (33%). In these
Centers, eight protocols are still active and recruiting patients. Six
out of seven centers (85%) were willing to share their protocols



























































Figure 1. Number of allogeneic transplants in solid tumors in EBMT Countries in 2009–2014 (a) and number of transplants per disease
2009–2014 (b). CRC: colo-rectal cancer; GCT: germinal cell tumor; OsteoSa: osteosarcoma; LMS: leiomyosarcoma; NBL: neuroblastoma;
OsteoSa: osteosarcoma; RCC: renal cell cancer; RMS: rhabdomyosarcoma; STS: soft-tissue sarcoma.
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participated in the survey) would be interested in a common
EBMT protocol, and 13 (72%) would agree to provide their data for
publication. To the last question (‘Would you continue to offer
alloSCT for solid tumors?’), 3 centers answered no, 10 centers
answered yes (55%) and 3 additional centers replied yes with
further specifications (yes, with additional cellular therapy; yes
after discussion; yes in very special situations; 72%; Table 3).
This survey provided a picture of the status of allogeneic
transplantation for solid tumors in EBMT centers. In contrast to our
expectations, allogeneic transplant for solid tumors has not been
abandoned, even if its use has been markedly reduced. The
response rate of the centers to the survey was low (18/38, 47%), as
expected since most Centers reported just one transplant. This
procedure was mostly used in Italy and Germany, and in a few
other centers in France and Austria, mostly for young adults with
tumors that are frequent in the pediatric population (rhabdomyo-
sarcoma, Ewing’s sarcoma and neuroblastoma), and in a few cases
of ‘adult-type’ tumors (breast, ovarian and pancreatic cancer). With
the exception of HER2-positive breast cancer, these are tumors in
which few advances have been made in the last years with
targeted therapies. As expected, many transplants have been
performed outside a clinical protocol, a behavior that should be
avoided in case of experimental procedures.
In conclusion, allograft for solid tumors as adoptive
immunotherapy is still being used in EBMT Centers, in a few
centers and in a few selected indications. Centers are willing to
share data, adopt common protocols and continue to use this
strategy in highly selected cases.
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Table 1. Number of centers per country









Table 2. Diagnosis of solid tumors
Diagnosis No. of transplants %
Rhabdomyosarcoma 9 28
Ewing sarcoma 7 22
Breast carcinoma 4 12
Neuroblastoma 3 9
Ovarian carcinoma 1 3
Mesenchymoma 1 3
Thymoma 1 3
Colorectal adenocarcinoma 1 3
Soft tissue sarcoma 1 3
Other kidney tumor including renal cell 1 3
Bone sarcoma (excluding Ewing/primary
neuroectodermal tumors)
1 3
Testicular carcinoma 1 3
Pancreatic cancer 1 3
Table 3. Answers to questionnaire
No. %
Would you share your protocol?
No 1
Yes 6 85
Would you be interested in an EBMT protocol?
No 2
Yes 7 77





Would you continue to offer alloSCT for solid tumors?
No 3
Yes 10
Yes, with additional cellular therapy after auto to
maintain remission
1 72
Yes, after discussion 1
Yes, in very special situations 1
Missing 2
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